| Name | Title | Contact Details |
|---|---|---|
Sergio Mirallesto |
Executive Vice President and Chief Information Officer | Profile |
Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.
Bisco Inc is a Schaumburg, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The new Actavis, Inc. (NYSE:ACT) is a combination of the previously separate Watson Pharmaceuticals, Inc. and Swiss-based Actavis Group. Actavis, Inc. is a specialty pharmaceutical company that develops, manufactures and distributes generic, brand and biosimilar products. The Company has global headquarters in Parsippany, NJ and international headquarters in Zug, Switzerland.
Smart devices and digital support that connect patients to care, with clinically-proven results https://t.co/zoMxznOfwA
Crunch is a No Judgment Gym that believes in making serious exercise fun by fusing fitness and entertainment. Join Crunch for all your fitness needs!